Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Total Liabilities: 2020-2025

Historic Total Liabilities for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $7.0 million.

  • Mereo BioPharma Group's Total Liabilities fell 56.79% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 56.79%. This contributed to the annual value of $15.4 million for FY2024, which is 3.39% down from last year.
  • As of Q3 2025, Mereo BioPharma Group's Total Liabilities stood at $7.0 million, which was down 17.15% from $8.5 million recorded in Q2 2025.
  • Mereo BioPharma Group's 5-year Total Liabilities high stood at $89.8 million for Q2 2021, and its period low was $7.0 million during Q3 2025.
  • For the 3-year period, Mereo BioPharma Group's Total Liabilities averaged around $12.7 million, with its median value being $14.3 million (2024).
  • Data for Mereo BioPharma Group's Total Liabilities shows a maximum YoY crashed of 56.79% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Mereo BioPharma Group's Total Liabilities stood at $51.8 million in 2021, then plummeted by 49.77% to $26.0 million in 2022, then crashed by 38.63% to $16.0 million in 2023, then declined by 3.39% to $15.4 million in 2024, then crashed by 56.79% to $7.0 million in 2025.
  • Its last three reported values are $7.0 million in Q3 2025, $8.5 million for Q2 2025, and $8.2 million during Q1 2025.